Latest Conference Articles

Tom Greenlee, retail pharmacy manager at the University of Missouri Health Care, and Kayla Hodges, 340B Analyst in Pharmacy Business at the University of Missouri Health Care, discuss how a successful career ladder can help retain pharmacy technicians.

Getting payers on board will be key to national biosimilar cost-savings potential.

A survey of women in New York confirmed that nearly three-quarters would be comfortable getting a contraceptive prescription from a pharmacist.

Increasing workplace diversity, addressing health disparities, and overcoming disruptions from COVID-19 are considered top goals among pharmacy stakeholders.

O’Mally Monahan, vice president of Operations at McKesson RxO, discusses patient assistant programs and how they can reduce a delay in treatment.

Pharmacists concluded that the workflow could be implemented for any drugs that are in short supply.

Michelle Condren, PharmD, AE-C, BCPPS, CDCES, FPPA, discussed pharmacists' roles in inpatient diabetes management.

Results suggest pharmacists should use the phrase “bad reaction” to avoid stigma associated with the term “overdose.”

Three key opportunities for oncology stewardship are dose rounding, implementation of biosimilars, and management of sites of care.

Implementing screening tools, conducting brief interventions, and involving pharmacists can help manage alcohol use disorder and Alcohol Withdrawal Syndrome.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

Pharmacy Times® will be onsite in Texas providing written and video content for the SABCS, which takes place December 6 to 10.

Pharmacy Times will be covering the American Society of Health-System Pharmacists 2022 Midyear Clinical Meeting from December 4 to 8.

Data to be presented at the 45th Annual San Antonio Breast Cancer Symposium suggest that the novel sequencing test can detect signs of disease recurrence across breast cancer subtypes, improving outcomes.

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

Patients administered 75 mg or higher of olpasiran every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Evolocumab found to reduce reduced adverse cardiovascular events in combination with statin therapy compared to placebo plus statin therapy.

The American Heart Association issued a dietary guidance in 2021 suggesting that adults consume a variety of fruits and vegetables, choose whole grains instead of refined grains, eat healthy protein sources and lean cuts of meat, and substitute nonfat and low-fat dairy products for full-fat versions, among other measures.

In 2020, heart disease death rates increased in adults across all age, sex, racial and ethnic groups, specifically among younger adults and non-Hispanic Black adults.

Poster presentations and speaking sessions at NASP showed the importance of clinical pharmacists in ambulatory care and opportunities to expand specialty pharmacy services in ambulatory care.

A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

Session presenters at ASCP 2022 Annual Meeting discuss the benefits and disadvantages of apixaban versus warfarin for anticoagulation.

However, findings do not preclude the possibility that mechanisms other than cardiac remodeling may be responsible for benefits of SGLT2 inhibition.

Approximately 10% of patients in trial experienced a heart attack, stroke, blocked arteries requiring treatment, or death from cardiovascular disease.

Intravenous iron reduced the risk of hospitalization for heart failure or cardiovascular death by approximately 20%.

A session presenter at the ASCP 2022 Annual Meeting addresses research investigating the value of preventative treatments when patients have a limited life expectancy.

Chlorthalidone was associated with more individuals with potassium levels below 3.1 mmol/L, suggesting a greater risk of hypokalemia.